Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes

By Hanefeld Markolf   Herman Gary A.   Wu Mei   Mickel Carolyn   Sanchez Matilde   Stein Peter P.    

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1329-1339

Informa Healthcare

Access to resources Recommend Favorite

Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study

By Hassanein Mohamed   Hanif Wasim   Malik Waqar   Kamal Ali   Geransar Parnia   Lister Nicola   Andrews Chris   Barnett Anthony  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1367-1374

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 3, 2015-03 ,pp. : 309-312

John Wiley & Sons Inc

Access to resources Recommend Favorite

How attractive is the combination of a sodium glucose co‐transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes?

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 613-615

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study*

By Pratley Richard E.   Reusch Jane E.-B.   Fleck Penny R.   Wilson Craig A.   Mekki Qais  

Current Medical Research and Opinion, Vol. 25, Iss. 10, 2009-10 ,pp. : 2361-2371

Informa Healthcare

Access to resources Recommend Favorite